Objective To analyze the effect of diammonium glycyrrhizinate enteric-coated capsules combined with fluticasone propionate cream on PASI score and serum inflammatory factor levels in patients with psoriasis vulgaris. Methods A total of 40 patients with psoriasis vulgaris admitted to Changzhou No.2 People's Hospital from May 2023 to December 2024 were selected as the research subjects. According to the random number table method, they were divided into the control group and the observation group, with 20 patients in each group. The control group was treated with fluticasone propionate cream, and the observation group was treated with diammonium glycyrrhizinate enteric-coated capsules. The clinical efficacy, Psoriasis Area and Severity Index (PASI) score, serum inflammatory factor levels and adverse reaction rate were compared between the two groups. Results The total effective rate of treatment in the observation group was 95.00%, which was higher than 70.00% in the control group (P <0.05). After 2, 4, 6, and 8 weeks of treatment, the PASI score in the two groups was lower than that before treatment, and that in the observation group was lower than that in the control group (P <0.05). After 8 weeks of treatment, the levels of IL-6 and TNF-α in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The application of diammonium glycyrrhizinate enteric-coated capsules in combination with fluticasone propionate cream in the treatment of psoriasis vulgaris can promote the improvement of the symptoms and serum inflammatory factors of patients, has a better treatment effect, and does not increase adverse reactions, which is worthy of application.